Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 801 to 810 of 881 total matches.
Paliperidone (Invega) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Mar 12, 2007 (Issue 1256)
) for Ulcerative Colitis
Dermal Fillers
Coming Soon in Treatment Guidelines:
Drugs for Pain — April 2007
Choice ...
Paliperidone (Invega - Janssen) has been approved by the FDA in an extended-release formulation for treatment of schizophrenia. It is the primary active metabolite of the second-generation antipsychotic risperidone (Risperdal - Janssen), which is scheduled to lose its patent exclusivity in December 2007.
MoviPrep: A New Bowel Prep for Colonoscopy
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007 (Issue 1262)
of other PEG-based solutions.
ADVERSE EFFECTS — Abdominal distension and
pain, nausea, anal discomfort ...
MoviPrep (Salix) is a new polyethylene glycol (PEG)-based bowel cleansing preparation approved for use in adults prior to colonoscopy. It contains ascorbic acid, which acts as an additional cathartic and flavoring agent, and requires a lower volume of fluid (3 L compared to the traditional 4 L) than most other PEG products. HalfLytely is an FDA-approved 2-L PEG product, but it must be taken with bisacodyl.
Desvenlafaxine for Depression
The Medical Letter on Drugs and Therapeutics • May 19, 2008 (Issue 1286)
particularly for treatment of depression in patients with prominent pain complaints.
Table 1. SNRIs and SSRIs ...
The FDA has approved the marketing of desvenlafaxine (Pristiq - Wyeth), the main active metabolite of venlafaxine (Effexor, and others - Wyeth), for treatment of major depressive disorder. Venlafaxine, a norepinephrine and serotonin reuptake inhibitor (SNRI), is available generically as an immediate-release tablet. Venlafaxine extended-release capsules (Effexor XR) are scheduled to go off-patent in 2010.
Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis
The Medical Letter on Drugs and Therapeutics • Mar 23, 2009 (Issue 1308)
with dexlansoprazole
than with placebo included diarrhea, abdominal pain,
upper respiratory infection, nausea ...
The FDA has approved the proton-pump inhibitor (PPI) dexlansoprazole (Kapidex - Takeda), a delayed release formulation of the R-enantiomer of lansoprazole (Prevacid - Takeda), for treating and maintaining healing of erosive esophagitis and for treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD).
Dronedarone (Multaq) for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Oct 05, 2009 (Issue 1322)
— Diarrhea, nausea, abdominal pain and vomiting can occur with dronedarone,
but unlike amiodarone ...
Dronedarone (Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but has considerable toxicity.
Degarelix (Firmagon) for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Oct 19, 2009 (Issue 1323)
prostate cancer, including increased bone
pain due to metastatic disease, urinary obstruction ...
The FDA has approved degarelix (Firmagon - Ferring), a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist, for rapid medical castration of men with advanced prostate cancer. Abarelix (Plenaxis), the first GnRH antagonist approved by the FDA, was withdrawn from the US market because of immediate hypersensitivity reactions.
Ophthalmic Besifloxacin (Besivance)
The Medical Letter on Drugs and Therapeutics • Dec 14, 2009 (Issue 1327)
have
included blurred vision, eye pain, eye irritation, eye
pruritus and headache. Besifloxacin is classified ...
The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension (Besivance - Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the manufacturer, this product was developed specifically for ophthalmic use in a specialized vehicle designed to prolong contact time on the ocular surface. Besifloxacin is not available for systemic use.
A New Conjugate Meningococcal Vaccine (Menveo)
The Medical Letter on Drugs and Therapeutics • Jul 26, 2010 (Issue 1343)
disease.
1
ADVERSE EFFECTS — The most common adverse
reactions to Menveo have been injection site pain ...
The FDA has approved Menveo (Novartis), a new quadrivalent conjugated polysaccharide vaccine, for
protection against disease caused by Neisseria meningitidis in people 11-55 years old.
Colonoscopy Preparations
The Medical Letter on Drugs and Therapeutics • Jan 21, 2013 (Issue 1408)
, vomiting, bloating and abdominal pain can
occur. Since these preparations may cause electrolyte ...
Colonoscopy remains the preferred method of colorectal
cancer screening. Many patients consider
cleansing the bowel in preparation for colonoscopy
the most unpleasant part of the procedure, but inadequate
bowel preparation significantly lowers the diagnostic
yield.
Glycopyrrolate/Formoterol (Bevespi Aerosphere) for COPD
The Medical Letter on Drugs and Therapeutics • Oct 10, 2016 (Issue 1505)
of inhaled beta2-adrenergic
agonists include palpitations, tachycardia, chest
pain, tremor, nervousness ...
The FDA has approved a fixed-dose combination of
the long-acting anticholinergic glycopyrrolate and
the long-acting beta2-adrenergic agonist (LABA)
formoterol (Bevespi Aerosphere – AstraZeneca) for
long-term maintenance treatment of patients with
chronic obstructive pulmonary disease (COPD).
Glycopyrrolate/formoterol is the fourth long-acting
anticholinergic/LABA combination to be approved in
the US, but the first to become available in a metered-dose
inhaler. Glycopyrrolate/indacaterol (Utibron
Neohaler), umeclidinium/vilanterol (Anoro Ellipta),
and tiotropium/olodaterol (Stiolto...